Table 1.

Demographics, baseline laboratory values, and parathyroid gland size

CharacteristicCinacalcet Trial ParticipantsHistorical ControlsP
Group S (n = 56)Group L (n = 25)Group HS (n = 65)Group HL (n = 22)
Age (years)62 ± 1166 ± 1261 ± 1060 ± 70.11
Gender (%)
    men646063640.99
    women36403736
Duration of dialysis (months)194 ± 108162 ± 79204 ± 117229 ± 890.18
Primary cause of renal failure (%)
    glomerulonephritis638060860.35
    diabetes188110
    hypertension2435
    pyelonephritis4400
    polycystic kidney disease4030
    others74179
    unknown4060
Use of vitamin D sterols (%)9384941000.19
    maxacalcitol485245680.29
    calcitriol2320800.014
    oral vitamin D211242320.018
Use of phosphate binders (%)919688860.62
    calcium carbonate594082640.001
    sevelamer hydrochloride687249360.015
Dialysate calcium (%)
    2.5 mEq/L6252235<0.001
    3.0 mEq/L38487795
Intact PTH (pg/ml)508 ± 187765 ± 468554 ± 292726 ± 270<0.001
Serum calcium (mg/dl)9.7 ± 0.510.0 ± 0.59.3 ± 0.89.9 ± 0.3<0.001
Serum phosphorus (mg/dl)6.0 ± 1.16.0 ± 1.66.3 ± 1.26.0 ± 1.20.55
Parathyroid gland volume (mm3)
    total volume377 ± 2401479 ± 1029343 ± 2681076 ± 349<0.001
    volume of the largest gland231 ± 1301065 ± 1034216 ± 154667 ± 181<0.001
  • Plus-minus values are mean ± SD.